61-70 of 77 results
Discussion Paper: Biologic medicines and biosimilars in the Australian landscape - The challenges and the opportunities
Allens is engaging with stakeholders on the challenges and opportunities presented by biosimilars As part of this engagement we highlight a number of key issues for discussion and comment ...
Audio: D'Arcy v Myriad: The High Court rules on gene patenting
Allens Partner Dr Trevor Davies discusses why the High Court overturned the decision and what it means for the biotech industry ...
TGA confirms its approach to disclosure of commercially confidential information
The Therapeutic Goods Administration has released the final version of a document outlining its approach to the disclosure of commercially confidential information including information provided by medicine sponsors This follows the release of a draft version in June 2013 and a period of public and ...
Allens advises Healthscope on sale of medical centres business
Allens has advised Healthscope Limited, one of Australia's leading private healthcare operators, on the sale of its Australian medical centres business to Fullerton Health, a leading provider of ...
Allens advises on Australian-first dementia village
Allens has provided pro bono advice to Social Ventures Australia on the financing of the ground-breaking Korongee dementia care village. The first of its kind in Australia, the village is designed ...
Allens advises EBOS Group on acquisition of HPS
Allens has advised EBOS Group Limited on the proposed purchase of HPS, Australia's largest provider of outsourced pharmacy services. The acquisition of HPS - from Blue Sky Private Equity and a numb ...
Allens advises Healthe Care on two major acquisitions
Allens has advised leading Australian private hospital operator Healthe Care Australia in relation to the acquisition of ASX-listed Pulse Health Limited and three hospitals in the Illawarra region ...
Dixon Hospitality says cheers to Beer DeLuxe
Allens has advised Dixon Hospitality on its acquisition of the Beer DeLuxe venues in NSW and Victoria. Dixon has acquired six venues including those in the entertainment precincts of King Street ...
Allens advises Healthscope on sale of Australian pathology business
Allens has acted for one of Australia's leading private healthcare operators, Healthscope Limited, on the sale of its Australian pathology operations to Crescent Capital Partners for $105 million. ...
Protecting innovation without patents - data exclusivity and market exclusivity
Developments in patent law and the consequential limitations on patentability for biologic medicines mean that data exclusivity and market exclusivity can be the primary protection afforded to originator biologic medicines This is most stark in the US where patent protection for biologic medicines ...